ArticleRheumatology (Oxford, England)2022

Long-term treatment in rheumatoid arthritis: do biological and targeted-synthetic DMARDs increase the risk of malignancy?

Filippo Fagni et al.PubMed ↗Publisher ↗

No numbers read from the abstract.